Microscopic Polyangiitis (MPA) Clinical Trial
Official title:
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Efficacy and Safety Study of IFX-1 in Add-On to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
The purpose of this study is to investigate the safety and tolerability of two dose regimens of IFX-1 as add-on to standard of care (SOC) in subjects with GPA and MPA compared with placebo.
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are related systemic v anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a potentially life-threatening disease. GPA is a necrotizing vasculitis predominantly involving small- to medium-sized vessels (e.g., capillaries, venules, arterioles, arteries, and veins). MPA is a necrotizing vasculitis that primarily affects capillaries, venules, or arterioles, most commonly manifesting as necrotizing glomerulonephritis and/or pulmonary capillaritis. MPA. Primed neutrophils are activated by ANCA and generate C5a that engages C5a receptors on neutrophils. Therefore, patients with ANCA-related disease have elevated plasma and urine levels of C5a in active disease and not in remission. IFX-1 is a monoclonal antibody specifically binding to the soluble human complement split product C5a and the resulting nearly complete blockade of C5a-induced biological effects may be effective in the treatment of subjects with AAV. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03920722 -
Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis
|
Phase 3 | |
Recruiting |
NCT02593565 -
Vasculitis Pregnancy Registry
|
||
Completed |
NCT03919825 -
Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis (PEXIVAS) - Glucocorticoids
|
Phase 3 | |
Completed |
NCT00987389 -
Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
|
Phase 3 | |
Completed |
NCT02507024 -
The ANCA Vasculitis Questionnaire (AAV-PRO©)
|
N/A | |
Recruiting |
NCT03004326 -
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
|
||
Completed |
NCT03895801 -
Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
|
Phase 2 |